Last updated: April 24, 2026
What standards govern patentability for biopharmaceutical inventions in Lithuania?
Lithuania applies the European patent framework (EPC) through the national route and via validation of European patents. For biopharmaceuticals (small molecules, biologics, nucleic acids, antibodies, vaccines, and diagnostics when claimed as inventions), the practical gatekeepers are the same across the region: novelty, inventive step, industrial applicability, and claim clarity plus sufficiency.
Core patentability tests (EPO/EPC approach applied in Lithuania)
Lithuanian exam practice follows EPC principles for:
- Novelty (EPC Art. 54): the claimed subject matter must not be disclosed in a single prior-art reference.
- Inventive step (EPC Art. 56): the claim must not be obvious to a person skilled in the art in light of prior art.
- Industrial applicability (EPC Art. 57): the invention must be capable of industrial use.
- Sufficiency of disclosure (EPC Art. 83): the description must enable the invention across the full claimed scope.
- Clarity and support (EPC Art. 84): claims must be clear and supported by the description.
- Exclusions/limitations (EPC Art. 53): certain subject matter is not patentable, including essentially “discoveries,” and inventions are limited by rules on morality and ordre public.
Actionable impact for biopharmaceuticals
- Sequence, variant, and “broad genus” claims are assessed for whether the patent teaches a reliable way to produce the claimed molecules biologically and reproducibly, not just conceptually.
- Method claims for treatment require careful drafting to avoid claim categories that can be restricted in practice (see enforceability section).
- Functional definitions (for example, “binds to X,” “neutralizes Y,” “inhibits Z”) face heightened scrutiny when they expand beyond what is enabled.
Sources: EPO/EPC provisions on novelty, inventive step, industrial applicability, disclosure, clarity, and exclusions [1].
How does “novelty” play out for biologics and biosimilars?
Novelty in biopharma is usually determined at the reference-by-reference level. The biggest novelty risk is that a single earlier document discloses either:
- the same sequence or sufficiently specific structural/functional characterization;
- the same therapeutic use with the same dosage regimen where the claim is tightly tied to the prior art; or
- a claimed biologic defined by too-complex or under-specified features that still fall within the disclosure of prior art examples.
High-risk claim archetypes for novelty
- Broad antibody claims defined only by function or binding to a target without defining the epitope or sequence with sufficient precision to distinguish from prior art.
- Engineered proteins/variants defined by “percentage identity” or “mutations at positions A, B, C” when earlier disclosures cover intermediate variants.
- Nucleic acids and expression constructs defined by general hybridization rules or degenerate sequences.
Low-risk novelty patterns
- Claims tethered to specific sequence identifiers or well-defined structural features that are not present in a single prior art reference.
- Therapeutic or prophylactic uses anchored in new patient group logic only when the claim language is structurally anchored to a novel aspect (not just a label for an existing treatment).
Sources: EPC Art. 54 framework and novelty assessment methodology [1].
What is the inventive-step battleground for biopharmaceutical claims in Lithuania?
Inventive step is where biopharma portfolios tend to fail if claims are written as broad genus without a clear technical contribution over known alternatives.
EPO-style inventive-step logic applied in Lithuania practice
For biopharmaceutical inventions, examiners typically:
- identify the closest prior art;
- determine the objective technical problem; and
- assess whether the claimed solution would be obvious in view of the prior art plus common general knowledge.
Key pitfalls
- “Better results” claims without enabled comparative evidence: If the application does not provide technical proof for an improved effect across the full breadth, inventive step becomes vulnerable.
- Outcome-driven functional claims: If the claim result reads as an expected property rather than a demonstrated technical effect, inventive step is harder to defend.
- Overbroad genus claims: If the genus covers many variants, but only a subset is validated, examiners often treat the remainder as not credibly improvable.
Sources: EPC Art. 56 inventive step [1].
How does sufficiency of disclosure constrain claim scope for biologics?
Lithuanian examination follows the sufficiency standard aligned with EPC Art. 83. For biologics, this is one of the most decisive constraints on enforceable claim breadth.
Sufficiency pressure points
- Sequence-defined biologics: The patent must enable production and functional realization. For antibodies, enablement must cover the functional claim boundary.
- Functional definitions: If a claim defines the invention by activity rather than by structure, the disclosure must provide a direct and reproducible pathway for obtaining molecules that satisfy the function.
- Production and manufacturing: While the manufacturing method is not always claimed, the disclosure must still enable the invention.
Practical drafting consequences
- Genus claims often need:
- additional examples,
- clearer characterization,
- and an enabling rubric for generating variants that remain within the claim boundary.
Sources: EPC Art. 83 sufficiency requirement [1].
How does claim clarity and support limit enforceability?
Clarity and support affect both prosecution and later enforcement. If a claim is ambiguous, it may be narrowed during examination, and courts can interpret it conservatively at enforcement.
Common clarity issues in biopharma
- “Comprising” language that unintentionally expands into prior-art systems.
- Function-only definitions with undefined parameters (assays, thresholds, or binding/neutralization metrics).
- Variants defined with imprecise boundaries (for example, vague “conservative substitutions” without mapping).
Sources: EPC Art. 84 clarity and support [1].
What enforceability constraints exist for biopharmaceutical patents in Lithuania?
Enforceability in Lithuania is shaped by:
1) claim validity under European patent law principles;
2) category-specific limitations for medical treatment claims;
3) exhaustion and infringement doctrines in national law; and
4) patent term and lifecycle tools (where applicable).
The key enforceability insight for biopharma is this: claim category and wording determine what an infringer can do without triggering literal infringement, and they determine whether doctrine-of-equivalents arguments remain effective.
Sources: EPC framework and general European enforcement principles aligned with EPC [1].
How do claim categories affect enforceability for biopharma?
Swiss-type / medical use formats
Lithuania follows the European medical use claim framework. Practically:
- First/second medical use claims: typically enforceable when drafted within recognized EPC/EU formats.
- Methods of treatment of the human or animal body by therapy: are generally excluded from direct protection in classic “treatment method” form under EPC rules. The correct medical use claim format is what drives enforceability.
Sources: EPC Art. 53 exclusions for methods of treatment and related European practice [1].
Product claims vs use claims
- Product-by-structure claims (sequence/structural/defined composition) can support broader enforcement against supply and manufacturing of the covered product.
- Use claims can be narrower but can survive prior art better when the product is known but the use is new.
- Process claims can face enforceability friction if evidence of infringing process steps is hard to obtain.
Sources: EPC approach to claim categories and exclusions [1].
What are the main “scope of claims” levers for biopharmaceutical patents in Lithuania?
For Lithuanian filings and validated European patents, scope is determined mainly by:
- Claim drafting granularity (sequence vs function; dosage vs general use),
- Support and enablement (EPC Art. 83/84),
- Novelty/inventive-step boundaries created during prosecution,
- Interpretation rules when enforcing.
Scope levers that work in practice
- Tether breadth to concrete structural definition
If the invention is a molecule class, the claim should define what makes molecules fall inside the class.
- Use thresholds and assay definitions for functional claims
If “binds to target” is the definition, the patent should specify binding measurement and threshold conditions.
- Define patient group or regimen only when it is technically relevant
Regimen language can narrow scope, improve novelty, and reduce prior art collisions.
- Include alternative embodiments to support genus coverage
Multiple exemplars help defend broad genus claims and strengthen sufficiency.
Sources: EPC Art. 83 and Art. 84 [1].
What lifecycle and timing factors matter for enforceability in Lithuania?
Biopharmaceutical enforcement typically relies on:
- patent term,
- any eligible supplementary protection mechanisms (where relevant for pharmaceuticals),
- and ensuring the claim scope covers the marketed formulation or biologic.
Lithuania operates within the broader EU legal ecosystem for supplementary protection for medicinal products. Where applicable, these mechanisms can extend effective market exclusivity beyond the core patent term, but only if eligibility criteria are met.
Sources: European framework for patent and medicinal product protection mechanisms (EPC and EU-aligned practice) [1].
What claim strategies maximize probability of grant and enforceability?
This section translates the legal tests into portfolio actions.
1) Build a “two-layer” claim set
- Layer A: narrow anchor claims
Sequence-defined biologics (or explicitly defined constructs), and tightly specified therapeutic use.
- Layer B: broader genus claims with support
Variant families defined by mapped structural features and enabled via examples and characterization.
This structure reduces total portfolio fragility: if the genus is attacked on sufficiency or inventive step, anchor claims remain enforceable.
Sources: EPC Art. 83/84 [1].
2) Avoid functional-only breadth unless fully enabled
If the core differentiator is function, the patent must still teach how to obtain molecules with that function across the claim range.
Sources: EPC Art. 83 [1].
3) Use dosage and regimen language as a novelty tool
For use claims, dosage and regimen can create meaningful distinction when supported and linked to technical data.
Sources: EPC Art. 54 and Art. 56 frameworks [1].
4) Keep claim language consistent with the specification
During prosecution, amendments can shift claim meaning. Enforceability tracks how broadly the claim remains supported and enabled.
Sources: EPC Art. 84 [1].
How should you think about prior art when targeting biopharma claim scope?
Because Lithuania applies EPC-style novelty and inventive-step tests, prior art includes published documents and public availability. The critical practical point is that biopharma patents often fail by:
- overstating novelty against a single earlier disclosure,
- assuming “obviousness” cannot be proven for biologics, and
- treating differences that are not credibly tied to the technical problem.
Sources: EPC Art. 54 and Art. 56 [1].
What can be protected for biopharma under Lithuania’s framework?
In practice, claimable subject matter includes:
- biologics defined by sequence/structure/composition,
- engineered proteins/antibodies/vaccines,
- nucleic acids and expression systems,
- diagnostic markers when drafted as inventions (and not merely discoveries),
- medical uses when drafted in recognized forms.
Exclusions and limitations still apply.
Sources: EPC Art. 53 and claim frameworks [1].
Key Takeaways
- Patentability in Lithuania for biopharmaceutical inventions follows EPC tests: novelty, inventive step, industrial applicability, sufficiency (Art. 83), and clarity/support (Art. 84).
- Biopharma claim scope is constrained most often by sufficiency and clarity, especially for genus and function-based definitions.
- Enforceability depends heavily on claim category correctness for medical use and on whether the claim breadth remains consistent with what the application enables.
- The highest-leverage claim strategy is a two-layer approach: narrow anchor claims plus broader genus claims that are demonstrably enabled and well-defined.
FAQs
1) Can I enforce a biopharma patent in Lithuania if my claim is a method of treatment?
Enforceability depends on using recognized EPC-compatible medical use claim formats rather than relying on classic excluded treatment-method framing.
2) Do functional definitions like “binds to” or “neutralizes” expand risk in Lithuania?
Yes. Functional-only breadth is more likely to be attacked on sufficiency and clarity unless the patent teaches how to make and characterize molecules that meet the function across the full claim range.
3) What is the biggest driver of claim narrowing for biologics during prosecution?
Sufficiency and inventive step pressures on broad genus definitions, especially when only limited embodiments have technical evidence.
4) How do dosage and regimen details affect scope?
They can narrow scope to preserve novelty and reduce prior-art collisions when supported by the specification and linked to demonstrated technical effects.
5) Are protein and antibody patents treated differently from small-molecule patents in claim scope?
The legal tests are the same, but biologics face heightened scrutiny because enablement and functional breadth must cover biological variability and reproducibility across the claimed class.
References (APA)
- European Patent Convention (EPC). (n.d.). Articles 53, 54, 56, 57, 83, and 84. European Patent Organisation.
